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Abstract
Background: It is clear that specific intestinal bacteria are involved in the development of different premalignant
conditions along the gastrointestinal tract. An analysis of the microbial constituents in the context of pancreatic cystic
lesions has, however, as yet not been performed. This consideration prompted us to explore whether endoscopically
obtained pancreatic cyst fluids (PCF) contain bacterial DNA and to determine the genera of bacteria present in such
material.
Methods: Total DNA was isolated from 69 PCF samples. Bacterial 16S rRNA gene-specific PCR was performed followed
by Sanger sequencing and de novo deep sequencing for the V3-V4 variable region of 16S rRNA gene.
Results: We observed that 98.2% of the samples were positive in conventional PCR, and that 100% of
selected PCF samples (n = 33) were positive for bacterial microbiota as determined by next generation
sequencing (NGS). Comprehensive NGS data analysis of PCF showed the presence of 408 genera of bacteria,
of which 17 bacterial genera were uniquely abundant to PCF, when compared to the Human Microbiome
Project (HMP) database and 15 bacterial microbiota were uniquely abundant in HMP only. Bacteroides spp.,
Escherichia/Shigella spp., and Acidaminococcus spp. which were predominant in PCF, while also a substantial
Staphylococcus spp. and Fusobacterium spp. component was detected.
Conclusion: These results reveal and characterize an apparently specific bacterial ecosystem in pancreatic cyst fluid
samples and may reflect the local microbiota in the pancreas. Some taxa with potential deleterious functions are
present in the bacterial abundance profiles, suggesting that the unique microbiome in this specific niche may
contribute to neoplastic processes in the pancreas. Further studies are needed to explore the intricate relationship
between pathophysiological status in the host pancreas and its microbiota.
Keywords: 16S rRNA gene, Pancreatic cyst fluid, Cystic tumors, Fusobacterium spp., Bacterial translocation, NGS, Human
Microbiome Project
Background
Pancreatic cysts are fluid-filled neoplasms that can be
detected with a frequency of up to 2% in the general
asymptomatic adult population and have a low, but not
negligible risk for evolving into pancreatic ductal adeno-
carcinoma, while accounting for up to 5% of the total
incidence of pancreatic cancerous lesions [1, 2]. The vast
majority of cysts are coincidentally found during cross-
sectional imaging done for other reasons than cyst-related
symptoms. Optimal clinical management of pancreatic
cysts remains controversial, but there is consensus in the
field that increased insight into the molecular pathogen-
esis of pancreatic cysts may guide development of rational
strategies in this respect. Unfortunately, the etiology of
pancreatic cysts remains largely obscure.
Progress with respect to understanding the nature and
natural history of pancreatic cysts is compounded by the
presence of different types of this lesion. Grutzmann et al.
and Farrell et al. have attempted to classify the different
types of pancreatic cyst lesions and distinguish among
others as intra-ductal papillary mucinous neoplasms
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(IPMNs), mucinous cystic neoplasms (MCN), serous
cystadenomas (SCA), and pseudocysts [3–5]. In general, it
is assumed that IPMN and MCN pose a higher risk of de-
veloping into carcinoma, with IPMN being more prevalent
compared with MCN [1, 6]. IPMNs are further classified
as main branch, side branch, or mixed types, based on the
involvement of the duct in the pancreas [5]. Presently,
there are no validated biomarkers to identify cystic lesions
that require surgical resection and this constitutes a major
challenge in this field. Although pancreatic lesions develop
into malignancy in only up to 3 % of cases, 10 % of pa-
tients with such lesions undergo resection [5] suggesting
the need for superior clinical tests and patients’ stratifica-
tion prior surgery. Currently, the decision for resection of
pancreatic cyst lesions and/or continued monitoring is
made according to the Sendai guidelines after evaluation
of different clinical tests [7–9]. The available clinical tests
include different biochemical analyses, cytology, patho-
logical assessment of fine needle biopsy or aspiration
material, endoscopic ultra-sonography (EUS), and
radiological diagnosis such as endoscopic retrograde
cholangiopancreatography (ERCP), magnetic resonance
cholangiopancreatography (MRCP), and whole-body com-
puterized tomography (CT). The inter-observer agree-
ment, however, between different modalities remains
moderate [10]. Therefore, a set of preoperative biochem-
ical analyses have been increasingly used in clinical
decision-making. This includes the study of cyst fluids
and serum for the characteristic presence of carci-
noembryonic antigen (CEA), cancer antigen 19.9
(CA19.9), cancer antigen 72.4 (CA72.4), cancer anti-
gen 15.3 (CA15.3), pancreatic amylase, and mucin an-
tigens, along with other cyst characteristics [11, 12].
Other tests are based on specific analysis of different
genetic modalities like K-RAS mutation and integrity,
but efforts attempting to provide clinical validation
for such tests have largely proven unsuccessful [1, 6,
13, 14]. Increased insight into the factors that facili-
tate the development of cystic lesions would evidently
benefit the identification of tests capable of providing
guidance for clinical management of asymptomatic
patients exhibiting pancreatic cysts.
Intriguingly, the human gut microbiome has
emerged recently as an important environmental fac-
tor linked to the development of different intestinal
and extra-intestinal malignancies [15–17]. In the
stomach, Helicobacter pylori remains the archetypical
example of a prokaryotic organism that can initiate a
cascade of molecular events finally leading to full-
blown cancer, whereas in the colon, various organisms
and especially Fusobacteria have been linked to the
appearance of dysplasia (reviewed in [17]). Whether
the appearance of pancreatic cysts is linked to the
presence of bacteria per se and if so whether specific
types of bacteria are associated to the presence of
cystic pancreatic neoplasms has remained unexplored.
If, however, the presence of pancreatic cyst can be
linked to the microbiome, this would entail a signifi-
cant step forward with respect to our understanding
of pancreatic cystogenesis.
The above-mentioned considerations prompted us to
explore the potential microbial component of pancreatic
cyst fluid. The results show that presence of bacterial
DNA is common to such material and that especially
Fusobacterium spp. and Bacteroides spp. are prominently
present in such material. As some of these bacterial
species have been linked to dysplastic processes elsewhere
in the tracts, a causal link between the presence of such
bacteria and pancreatic neoplasm may also exist and the
results may indicate that bacterial colonization of pancre-
atic cyst fluid is a regular phenomenon.
Methods
Patient samples and pancreatic cyst fluid collection
A cohort of 69 patients with suspected cystic lesions was
established between the period of 2008 and 2013 (Table 1
and Additional file 1).The pancreatic cyst fluids (PCF)
were collected after a signed informed consent from
these patients, who were undergoing endoscopic ultra-
sound fine needle aspiration (EUS-FNA) at the Depart-
ment of Gastroenterology, Erasmus MC, The Netherlands.
Following collection, pancreatic cyst fluids were trans-
ferred to the laboratory and stored at − 150 °C until
analysis.
DNA isolation
Approximately 300 μl from 69 pancreatic cyst fluid
samples were used for total DNA isolation. After bead
beating (Fast Prep®-24 Instrument), the supernatant
and pellet were separated by centrifugation at
13000 rpm for 1 min and both pellet and supernatant
were used for total DNA isolation, using the Wizard
DNA isolation kit as specified by the manufacturer’s
protocol (catalog no. A1620, Promega BNL B.V, The
Netherlands). Isolated DNA was equilibrated in the
DNA rehydration solution from the kit and quantified
on nanodrop-2000 spectrophotometer (Isogen Life
Science BV, De Meern, The Netherlands). Pancreatic
cyst fluid DNA was diluted to 1 ng/μl for the PCR
analyses and subsequently stored at − 20 °C.
PCR analyses
Total DNA isolated from pancreatic cyst fluids was used
for bacterial 16S rRNA gene detection using conven-
tional PCR. GoTaq® Flexi DNA polymerase kit (Promega
BNL B.V, The Netherlands) and universal 16S rRNA
primers were used (Bacteria cPCR-27F 5′-AGAGTTT-
GATCCTGGCTCAG-3′, Bacteria cPCR-1401R 5′-
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CGGTGTGTACAAGACCC-3′, 1394 bp product size,
PCR condition, 95 °C for 6 min; 30 cycles of 95 °C de-
naturation for 30s, 50 °C primer annealing for 30 s and
72 °C elongation for 90 s; and final elongation of 7 min
at 72 °C). The 16S rRNA gene amplicons were run on
1% agarose gels (Sigma Aldrich, The Netherlands), and
the positive samples were selected by the presence of
16S rRNA gene 1394 bp band (Fig. 1).
16S rRNA gene sequencing analyses
Sanger sequencing
Sanger sequencing was done in order to identify the
bacterial 16S rRNA genes present in the PCF. The
PCR products generated using universal primers of
16S rRNA were sequenced using F primer 5′-
CTTAGGAATGAGACAGAGATG-3′ through LGC
Genomics GMBH, Germany. The chromatograms
were analyzed, sequences were curated and identified
using web databases of integrated microbial genomes
and 16S rRNA-specific nucleotide BLAST. The
sequences have been deposited at NCBI under gene
accession identifiers MF061964–MF061990.
Deep sequencing
From this cohort of 69 PCF samples, DNA of 33 samples
[(47.8%), IPMN (n = 9), MCN (n = 7), Pseudocysts
(n = 8), and SCA (n = 9)] was selected for de novo 16S
rRNA gene amplicon sequencing by Macrogen (South
Korea). 16S rRNA gene amplicon sequencing was per-
formed on the V3-V4 variable region using Illumina
Miseq adapter PCR followed by clustering and sequen-
cing. The raw images generated are used by MCS
(MiSeq Control Software v2.4.1.3) for system control
and base calling through an integrated primary analysis
software called RTA (real-time analysis. v1.18.54.0). The
BCL binary (base calls) is converted into FASTQ utiliz-
ing illumine package MSR (MiSeq Reporter).
Deep sequencing data analysis
Two types of deep sequencing analyses were performed,
one with paired-end reads alone discarding the single
pair reads leading to 408 genera identification, and one
with paired-end reads and single pair reads leading to
identification of 785 genera [18]. The data generated via
paired-end reads alone was further used for downstream
analysis for comparison of the PCL bacteria population
Table 1 Characteristics and clinicopathological features of the patients with pancreatic cyst
Patient characteristics IPMN (n = 27) MCN (n = 13) Others (n = 11) Pseudocysts
(n = 9)
Serous
cystadenoma
(n = 9)
Types of cysts (%)
(n = 69)
Main branch
IPMN
2.9% No definite clinical
diagnosis (others)
6.0%
Mixed type IPMN 5.8% NET (others) 3.0%
Multifocal side
branch IPMN
5.8% Acinar cell carcinoma
(others)
1.0%
Side branch IPMN 17.0% Simple cyst (others) 3.0%
IPMN 7.2% Cystic GIST; no
communication PD
(others)
3.0%
Total percentage
of samples in each
pancreatic cyst
39.10% 18.8% 15.90% 13.0% 13.0%
Resected sample
percentage
11.6% 13% 4.3% 2.9% 0.0%
Dysplasia No Dysplasia 66.7% 53.8% 100% 100% 100%
Adenoma 11.1% 38.5% 0.0% 0.0% 0.0%
Moderate
dysplasia
11.1% 7.7% 0.0% 0.0% 0.0%
Carcinoma
in situ
11.1% 0.0% 0.0% 0.0% 0.0%
Gender Male 15.9% 0.0% 7.2% 7.2% 2.9%
Female 21.7% 17.4% 7.2% 5.8% 10.1%
Not available 1.4% 1.4% 1.4% 0.0% 0.0%
Average age 68 years 11 months
22 days
53 years
7 months
14 days
62 years 5 months
14 days
54 years
8 months
19 days
59 years
9 months
18 days
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vs human microbiome project samples of 13 different
body sites and comparisons between the types of clinic-
ally defined cysts types and resection (Additional file 1).
Pre-processing of amplicon reads and sequence data QC
Illumina Miseq sequence data was quality checked using
FastQC and Rqc software’s [19]. Base call quality distri-
bution, percentage of bases with quality scores above
Q20 and Q30, GC percentage, and sequencing adapter
contamination were used for assessing the data quality.
The details of the number of reads and base quality ob-
tained for each sample are provided in Additional file 2.
Taxonomic classification and OTU clustering
For downstream analysis of the metagenome data,
“mothur” software bundle was used [20].The quality-
filtered sequence reads were imported into mothur, and
the read pairs were aligned with each other to form con-
tigs based on sequence consensus. This results in longer
contigs that span the targeted V3-V4 hypervariable
region. These contigs were screened and only those be-
tween 470 and 500 bp were taken for further analysis.
Contigs with ambiguous base calls were rejected; high-
quality contigs were checked for identical sequences and
duplicates merged.
The filtered contigs were aligned to a known database
for 16S rRNA [Silva V.119] [21]. These classified contigs
were filtered for any undesired lineage from the tax-
onomy file. Any ambiguous contigs aligning to untar-
geted regions [other than V3-V4] were discarded. Using
UCHIME algorithm, chimeric contigs were flagged and
removed; a known reference for chimeric sequence was
cross referenced [22]. These final set of contigs were
then phylotype binned into operational taxonomic units
(OTU) based on the Silva V.119 database and the abun-
dance of each OTU in the population was estimated.
Comparison of the taxonomic classification of the
pancreatic microbiomes with those from other body sites
In order to identify microbial signature of pancreatic
cysts, a comparative analysis was carried out against
organ-specific bacterial profiles obtained from the NIH
Human Microbiome Project (HMP) database [23]. The
pancreatic microbial profile of the current study was
compared with microbial profiles of 13 different body
sites downloaded from HMP (SRA numbers provided in
Additional file 3). The notion that bacteria in the gut
Fig. 1 Abundance of bacterial DNA in pancreatic cyst fluid. A series of pancreatic cyst fluids (patient characteristics can be found by linking
sample name to the patient information provided through additional Table 1) were exposed to bead beating and centrifugation followed by
DNA extraction from both the pellet as well as the supernatant. Subsequently, the DNA was probed for the presence of sequence coding for
bacterial 16S RNA through PCR. Reaction products were resolved by gel electrophoresis employing an agarose gel. The results show that bacterial
DNA is commonly found in pancreatic cyst fluids
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may affect diseases outside the gut and vice versa is
gradually accepted, and we therefore considered both
anatomical sited in close proximity to the pancreas as
well as more distant sites.
The comparative analysis was carried out between
anterior nares, antecubital fossa, buccal mucosa, gin-
giva, hard palate, mid vagina, palatine tonsils, poster-
ior fornix, retroauricular crease, saliva, stool, throat,
and tongue. Although phylotype-based analysis is
limited as compared to distance-based OTU classifica-
tion, it allows for investigating the relationship of the
PCF microbiota to previously characterized microbes
in the HMP database.
Two analyses were performed for identifying the
unique microbiota when PCF commensals were com-
pared to the bacterial communities associated with 13
different body sites. First, a pairwise binomial test was
carried out against each organ in order to identify
significantly (FDR < 0.05, FC > 3) and absolute abun-
dance difference of 10 abundant bacterial species in
pancreas. Second, in order to identify the relatedness
of the PCF microbiomes with those from other body
sites, we compared bacterial communities of the PCF
samples to those of taxonomic profiles from 13 other
body sites from the HMP database by using principal
component analysis (PCA). Third, statistical compari-
sons of these microbiomes were performed using the
STAMP analysis package. The statistical tests used
was ANOVA and Welch’s t test, with Benjamini-
Hochberg multiple test corrections. Those taxa having
a higher abundance in the pancreatic cysts (with cor-
rected P value < 0.01) were identified as those that
are specifically abundant in the PCF.
Diversity analysis between the cyst types
Using STAMP statistical analysis package, those taxa
having a higher abundance between the test groups
IPMN vs pseudocyst vs MCN vs SCA were identified as
specific for the groups to be classified based on the bac-
terial population. The cysts were grouped based on the
pathological classifications, and they are tested using
White’s non parametric t test, two tailed with
Benjamini-Hochberg multiple test corrections of P value
(P < 0.05) [24]. The measured levels of CEA and CA19.9
ranges were used for classification of cysts as cysts,
benign cysts, and malignant cysts according to study
conducted by Talar-Wojnarowska et al. [25]. Then the
classified data was used for the specific bacterial taxa
identification between the resected types using the same
parameters.
Statistics and calculations
All the statistical analysis were done using excel, Graph-
pad Prism 5.0., and STAMP statistical analysis software.
When appropriate, results were Bonferroni corrected in
graphpad analysis and Benjamini-Hochberg multiple test
corrections in STAMP. P values < 0.05 (between cysts
and resection types) and < 0.01 [between body sites
(NGS)] were considered significant.
Results
Study sample characteristics
For analysis of the potential microbial component of
pancreatic cyst fluid (PCF), material collected from 69
patients was used. The characteristics of these pa-
tients are listed in Table 1 and Additional file 1. Of
the PCF analyzed, 27 were obtained from patients
harboring an IPMN (39.1%), including two patients
with main branch IPMN (2.9%), four patients with
mixed type IPMN (5.8%), 12 patients with a unifocal
side-branch IPMN (17.4%), and four patients present-
ing with a multifocal side-branch IPMN (5.8%). In
five patients, the type of IPMN was unclassified
(7.2%). In addition, our cohort contained 13 patients
with an MCN (18.8%), nine patients with pseudocysts
(13.0%), and nine patients with serous cystadenomas
(13.0%). Finally, the cohort contained 11 patients with
apparently multiple forms of cystic lesions, gastro-
intestinal stromal tumor (GIST), neuroendocrine tu-
mors (NET), or having no definitive clinical diagnosis
and for this study, these patient were classified as
“others” (15.9%). We concluded that this cohort
would allow the study of potential microbiological
constituents of PCF and to relate results to the clin-
ical phenotype of the patient from which the fluid
was obtained.
Bacterial DNA is commonly present in EUS-FNA-collected
pancreatic cyst fluids
As it is as yet unknown whether pancreatic cystic fluid
hosts a microbiological component, analyzed the EUS-
FNA-collected pancreatic cyst fluid obtained from our co-
hort for the presence of significant amounts of bacterial
DNA. Importantly, we found that the majority of these
fluid samples were rich for bacterial DNA, with 16S rRNA
PCR demonstrating the presence of bacterial DNA in 64
(92.8%) out of the 69 samples (Table 2 and Fig. 1). The
presence of bacterial DNA in cyst fluid did not statistically
relate to the type of lesion from which it was obtained (P
value > 0.99; χ2 test): in mucinous cystic neoplasms, 100%
of samples contained significant amounts of bacterial
DNA; in IPMNs, this number was 92.6%; in pseudocysts,
88.9% of PCF were positive for bacterial DNA; in serous
cystadenomas, 88.9%; whereas in the group of others
which included GIST, NET, and clinically undefined sam-
ples, 90.9% displayed significant amounts of bacterial
DNA (Additional file 1 and Table 2).
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Microbial composition of pancreatic cyst fluid with a
differential clinical aspect
The presence of a microbial component in PCF raises
obvious questions as to the identity of the organisms ap-
parently present in such fluid. Sanger sequencing of PCR
products generated using universal 16S rRNA demon-
strated that Fusobacterium spp. is present in 13 out of
all 69 PCF samples (18.84%). Another predominating
bacterium in PCF was Bacillus spp. which was present
in 16 out of 69 (23.19%) samples. The presence of other
bacteria was also noted which included Ruminococcus
spp., Staphylococcus spp., Caldimonas spp., Arthrobacter
spp., Acinetobacter spp., Bacteroides spp., Orpinomyces
spp., and Anaerococcus spp. (Table 2).
To confirm the presence of these bacteria and gain
more insight into the bacterial composition of the PCF,
DNA obtained from the 23 fluids containing the highest
apparent concentration of 16S rRNA copies were sent
out for 16S rRNA de novo sequencing of V3-V4 region,
using universal 16S rRNA primers which should allow
identification of the bacteria present in such fluid at least
on genus level. The results (shown in Fig. 2 and
Additional file 2) are consistent with the presence of di-
verse bacterial ecosystems in such fluids, with as most
predominant genera present Bacteroides, Escherichia/
Shigella, and Acidaminococcus, but in total, 408 different
genera were detected in the 33 samples analyzed, of
which 93 genera were found in at least 50% of PCF
samples analyzed. Different types of cysts were not sta-
tistically different with respect to microbial composition:
for none of the 408 genera, a Bonferroni-corrected
statistically significant difference in abundance was
detected when serous cystadenoma, pseudocysts, IPMN,
or mucous cystic neoplasm-derived fluids were com-
pared. Furthermore, when low P values (Bonferroni-un-
corrected P value < 0.05 but > 0.0001) were considered,
it appeared that such findings were limited to very low
abundant organisms (< 0.05% of all bacteria) that were
relative low in one of the groups compared, more indica-
tive of technical detection problems rather than a reflec-
tion of true biological differences between the groups
(Additional file 2). In apparent agreement with the
notion that the ecological niche provided by cyst fluid is
relatively similar between different cyst manifestations is
also the observation that the Shannon index for eco-
logical diversity (H′) (Fig. 3) is not different between the
different groups (P value = 0.99; one-way ANOVA).
Diversity within the cyst type and resections
There were no significant difference in the diversity of
bacterial microbiota seen in the 33 sample group of deep
sequenced data, between the cyst types, or between the
resected vs non resected groups or between the CA19.9
or CEA range-based classification groups. The results
were in accordance with the bacterial presence in the
Table 2 Bacterial ecosystems characteristics identified from the pancreatic cyst fluids using PCR, Sanger sequencing, and next-
generation sequencing (NGS)
Bacterial ecosystem characteristics
Patient characteristics IPMN (n = 27) MCN (n = 13) Others
(n = 11)
Pseudocysts (n = 9) Serous cystadenoma
(n = 9)
16S rRNA PCR
(universal
16S rRNA
gene
primers)
Bacteria
present
92.6% 100% 90.9% 88.9% 88.9%
Bacteria
absent
7.4% 0.0% 9.1% 11.1% 11.1%
Sanger
sequencing
Bacteria
detected
Bacillus spp. Fusobacterium
spp., Orpinomyces spp.
Anaerococcus spp.,
Caldimonas spp.,
Acinetobacter spp.,
Bacillus spp.
Fusobacterium spp.,
Bacillus spp., Orpinomyces
spp., Microcystis spp.,
Staphylococcus spp.
Fusobacterium
spp.
Caldimonas spp.,
Propionibacterium spp.,
Fusobacterium spp.,
Curvibacter spp.,
Escherichia spp.,
Bacillus spp.
Arthrobacter spp.,
Bacillus spp., Bacteroides
spp., Ruminococcus spp.
16S rRNA
(NGS)
(n = 33)
Bacteria
present
100% (n = 9) 100% (n = 7) NA 100% (n = 8) 100% (n = 9)
Bacteria detected
by 16S rRNA gene V3-V4
variable region NSG
(n = 33)
Bacteroides—15.45%
Escherichia/
Shigella—9.88%
Faecalibacterium—8.57%
Acidaminococcus—5.75%
Sphingomonas—4.87%
Others—55.49%
Bacteroides—17.06%
Escherichia/
Shigella—10.17%
Faecalibacterium—6.95%
Acidaminococcus—5.22%
Sphingomonas—6.48%
Others—54.12%
NA Bacteroides—16.59%
Escherichia/
Shigella—10.55%
Faecalibacterium—6.81%
Acidaminococcus—6.23%
Sphingomonas—5.40%
Others—54.42%
Bacteroides—16.73%
Escherichia/
Shigella—9.97%
Faecalibacterium—6.64%
Acidaminococcus—6.24%
Sphingomonas—4.81%
Others—55.62%
NA not applicable
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different types of cysts based on the universal primer
PCR sequencing.
Microbial composition of pancreatic cyst fluid suggests
the presence of a unique ecosystem
A comparison of 13 different body sites (Human Micro-
biome Project) with the PCF bacterial population
showed 26 unique bacterial genotypes in PCF when
compared with stool, 27 genotypes compared with
throat, 28 genotypes compared with tongue dorsum, and
36 unique bacterial genotypes in the PCF which are not
present within any of the other body sites selected (Fig. 4
and Additional file 4). ANOVA analysis, which is per-
formed to identify the effect size of the bacterial popula-
tion, reveals that 314 bacterial microbiota show an effect
size variation between the bacterial commensals in PCF
versus selected body sites, high effect size (0.1 to 0.9 and
P < 0.01) bacterial populations are shown in Fig. 5, and
total effect size variation is shown in Additional file 5.
The PCA of different body sites and PCF are shown in
Additional file 6: Figure S1. The Welch’s t test was per-
formed to identify the specific bacterial populations hav-
ing high and low abundance in the PCF when compared
to HMP selected body sites. A total of 136 bacteria
(Additional file 6: Figure S2 and Additional file 7) are
identified, of which 17 abundant bacteria in PCF were
highly unique and potentially pro-cancerous. They are,
in ascending order of abundance in PCF, Coprococcus
spp., Collinsella spp., Butyricicoccus spp., Ruminococcus
spp., Parabacteroides spp., Alistipes spp., Clostridium XI
spp., Gemmiger spp., Dorea spp., Lachnospiracea
incertae sedis spp., Blautia spp., Bifidobacterium spp.,
Fig. 2 Taxonomic composition of microbiological genera of pancreatic cyst fluid. DNA isolated from 33 pancreatic cyst fluid samples (selected based
on strong PCR signals for 16S) was characterized by 16S rRNA NGS for its microbiological composition. The numbers indicated correspond to the
sample names in Additional file 1. a Serous cystadenoma aspiration fluid microbiome. b Intraductal papillary mucinous neoplasm aspiration fluid
microbiome. c Pseudocyst aspiration fluid microbiome. d Mucinous cystic neoplasm aspiration fluid microbiome. e Legend of the pie chart
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Sphingomonas spp., Acidaminococcus spp., Faecalibac-
terium spp., Escherichia/Shigella, and Bacteroides spp.
(P < 0.0001). A role for many of these bacteria in initi-
ation and progression of colon, lung, and liver cancer
has been suggested [26]. The following 15 bacterial
genera were higher in all the 13 body sites used in this
analysis: Streptococcus spp., Propionibacterium spp.,
Lactobacillus spp., Fusobacterium spp., Corynebacterium
spp., Veillonella spp., Neisseria spp., Staphylococcus spp.,
Porphyromonas spp., Prevotella spp., Leptotrichia spp.,
Actinomyces spp., Capnocytophaga spp., Gemella spp.,
and Selenomonas spp. (P < 0.0001). These were also the
least abundant bacteria present in the PCF. This com-
parison suggests that the PCF fluid bacterial colonization
is unique and characterized by high abundant genera
which have a tendency to propagate in the cancerous
microenvironment, feeding the tumor (Fig. 6).
Discussion
In the current study, we have demonstrated that 92.8%
of a large and clinically representative collection of
pancreatic cyst fluids (PCF) is host to a complicated eco-
system of bacteria. The distinct bacterial community had
a rich species diversity which is very different from that
observed elsewhere in the proximal human digestive
tract. Although the EUS-FNA is not a sterile procedure,
7.8% of the PCF samples were negative for bacterial
DNA arguing that the procedure did not have a major
impact on our cultivation-independent bacteriological
findings. Furthermore, the ecosystem observed by deep
sequencing of pancreatic cyst material is inconsistent
with that expected from contamination by the oral,
nasal, pharyngeal, oesophageal, gastric, or duodenal
flora. Members of the genus Streptococcus constitute by
far the major component of the bacterial ecosystem in
the esophagus [27], but while streptococcus was de-
tected in all samples sequenced, it constitutes less than
1% of the total microbiota in any sample in our series,
with the exception of one sample obtained from an
IPMN. Likewise, the stomach is relatively sterile and
dominated by H. pylori. The genus Helicobacter, how-
ever, was rare in our analysis, this genus the 67th genus
in our ranking of our samples. Other bacteria found
regularly in the stomach include Streptococcus, Neisseria,
and Lactobacillus, and these species are not dominant in
our analysis (being ranked as the 18th, 129th, and 54th
most prevalent genus) [20]. Thus, the esophagus and
stomach are an unlikely source of major contamination
in our results. The duodenum can be home to substan-
tial bacterial content, as also evident from conditions
such as small intestinal bacterial overgrowth or SIBO.
Valeria D’Argenio et al. recently reported on the bacter-
ial composition of the duodenum in a cohort including
15 healthy individuals [28]. The most prevalent genus
emerging from this analysis was Propionibacterium,
which, although fairly often detected, was relatively rare
in our analysis of pancreatic cyst fluids, with its abun-
dance not even approaching 1% of the entire flora in any
of the samples tested. Other genera dominating the duo-
denal microbiota include Porphyromonas (ranked 76th
in cyst fluid), Streptococcus, Neisseria, and Heamophillus
(ranked 21st, 58th, and 57th in cyst fluid). Hence, the
bacteria we observed in cyst fluid widely diverges from
that expected if duodenal contamination was a major
factor. Indeed in an analysis of microbiome of the
healthy proximal tractus in our own institution (manu-
script in preparation), we observed that Streptococcus,
Veillonella, Prevotella, and Pseudomonas have the
highest relative abundance from distal esophagus to the
jejunum and proximal ileum. This situation is markedly
different from that observed in pancreatic cyst fluids
(although Prevotella was the 7th most abundant genus
in pancreatic cyst fluid, this is still markedly lower as
that observed in the proximal gastrointestinal tract of
volunteers). In apparent agreement, in a preliminary
series of experiments employing fluorescent in situ
hybridization on surgically obtained pancreatic cyst
Fig. 3 Shannon index for ecological microbial diversity in pancreatic
cyst fluids. Employing the NGS results from PCF-derived DNA, the
Shannon index for ecological diversity was calculated. There are no
significant differences in the ecological diversity of the microbiome
in the different types of PCF
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material, bacteria were apparent (not shown). Thus, the
most straightforward interpretation of results is that the
pancreatic cyst is home to a previously unsuspected and
also unique bacterial ecosystem.
The presence of such a bacterial ecosystem in pancre-
atic cysts raises important questions as to the role of the
bacteria present in such cysts in the development of
such structures. In general bacteria have been linked to
transformation and trans-differentiation of endodermal
epithelia, with H. pylori being the most important
example. The genus Helicobacter was only marginally
detected in pancreatic cyst fluid; other bacterial species
linked to transformation in the intestine were, however,
more prevalent. In particular, F. nucleatum, which is
relatively predominant in a fraction of the samples and
has been convincingly linked to neoplasm formation in
the colon, excites interest in this respect. Emerging evi-
dence suggests that Fusobacterium species detected in
pancreatic cancer tissues is associated with a worse clin-
ical outcome in pancreatic cancer patients [29]. But also
other bacteria seen in pancreatic cyst fluids, even if it is
at low abundance, may have a role here. Using NGS
technology, multiple studies have compared oral micro-
biota between healthy individuals and those with pancre-
atic cancer [4, 30]. Although no correlation between
known pro-oncogenic oral pathogens and pancreatic
cancer was detected, Lin et al. showed that pancreatic
cancer patients had significantly higher levels of Bacte-
roides genus compared to control subjects [30], which is
in agreement with our finding that Bacteroides spp. were
the most predominant genus in PCF. In addition, a
recent pilot study using 16S rRNA gene sequencing on
saliva specimens showed that while there was no differ-
ence in diversity of oral microbiota between patients
with pancreatic ductal adenocarcinoma (PDAC), IMPN,
or healthy controls, pancreatic cancer patients had
higher levels of members of the phylum Firmicutes while
healthy individuals were associated with higher relative
abundances of Proteobacteria [31]. Evidence gathered
from those studies supposes that pancreatic malignancy
may be associated with changes in abundances of some
groups of bacteria in the human digestive tract. There-
fore, dysbiotic microbiota in the upper digestive tract in-
cluding oral cavity may interrupt the unique ecosystem
in pancreatic cyst fluids along the neoplastic process in
pancreas. At bay with the notion of a causative role for
the bacterial flora in pancreatic cyst formation, however,
is the observation that both detection of bacteria per se
or the composition of the cyst flora did not show correl-
ation to clinical parameters and thus the role of the flora
in cystogenesis, if any, awaits further study.
Pancreatic infections mainly arise from translocation
of bacteria from the small bowel, and rarely from the
colon and oropharyngeal route as demonstrated by study
Fig. 4 Pancreatic cyst microbiome is unique among other human body microbiomes. Publicly accessible databases were mined for composition
of microbiomes at different human body sites and compared to those observed in PCF. It appears that there are 27 to 314 bacterial genotypes
differently present in the PCF when compared to the selected body sites when analyzed via pairwise binomial test with high abundance PCF
bacteria(P < 0.0001) and ANOVA test, respectively
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on Veillonella and Bifidobacterium spp. which were
identified in pancreatic abscesses [32]. A study of Brook
et al. has identified 158 bacterial species from pancreatic
abscesses, of which 77 isolates were aerobic and the
remaining 81 were anaerobic bacteria [33]. The most
commonly detected microorganisms in infected pancre-
atic pseudocysts include often not only opportunistic
bacteria like E. coli, Enterobacter spp., Klebsiella spp.,
and Staphylococcus spp. but also fungal isolates includ-
ing Candida albicans (15 case studies) [34]. Importantly,
EUS FNAB procedure caused serious Clostridium per-
fringens infections in five patients leading to pancreatitis
and pancreatic cyst formation, which required surgical
interventions [35]. Such studies illustrate the nature of
the bacterial transfer from the early to mid-gut
commensal bacteria to the pancreas. Yet none of these
earlier studies have directly proved the presence of
bacteria in the pancreatic cyst and its fluid. Its apparent
divergence from the flora in the duodenum is probably a
reflection of the specific conditions in pancreatic cysts
which include an absence of contact with the digestive
nutrient stream, an exposure to high levels of pancreatic
secretes and the presence of abundant mucus. At
present, clinical behavior of pancreatic cysts is very diffi-
cult to predict and adequate management of cysts repre-
sents one of the largest challenges in clinical
gastroenterology. It is tempting to speculate, however,
that changing conditions in cysts related to transform-
ation of the structure to full-blown malignant cancer
would also influence the milieu interieur formed by cyst
fluid and hence have a profound effect on the bacterial
composition. As such, changes in the bacterial commu-
nities may serve to detect such transformation in cyst-
forming structures and may become useful for guiding
clinical management.
Irrespective, however, of its potential as future diag-
nostic and prognostic marker, the present study shows
an as yet unknown bacterial ecosystem in pancreatic cyst
fluid. As it is evident that bacteria influence physiology
and pathophysiology of their interacting epithelia
Fig. 5 a, b Contribution of individual bacterial genera to the unique aspect of PCF fluid. For 82 different genera the relative in abundance in PCF
was compared to that 13 other body sites and the relative contribution to the PCF-specific nature of the microbiome spectrum was calculated. In
additional files information on a further 232 genera can be found. The results show that PCF contains a microbiome that is characterized by an
overall uniqueness that cannot be attributed to a single genus
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everywhere in the gut, it is well possible that such inter-
actions also exist in the pancreas and its cysts, and that
the biology of the pancreatic cysts is in important ways
shaped by this ecosystem. Studies addressing this possi-
bility are currently in progress.
Conclusions
The study reveals previously undescribed bacterial diver-
sity present in human pancreas and its cyst fluids. As
specific bacteria are associated with this body site, we
propose that such bacteria may carry the potential to in-
fluence the development of pathophysiological processes
in the pancreas. The study points out to the need to
further explore the microbiome in this specific niche for
diagnostic and therapeutic purposes.
Additional files
Additional file 1: Detailed patient characteristics, samples characteristic
of samples taken for NGS, gene accession numbers of Sanger sequenced
samples and SRA numbers for the NGS selected samples, NGS sequenced
V3-V4 variable regions of 16S rRNA. (XLSX 26 kb)
Additional file 2: Detailed quality of reads, taxonomic profiles,
taxonomic distribution and taxonomic distribution rank. (XLSX 432 kb)
Additional file 3: SRA numbers of Human Microbiome Project used for
comparisons. (XLSX 93 KB)
Additional file 4: Selected Bacterial counts of the PCF and selected
body sites used for the binomial pairwise comparison. (XLSX 69 kb)
Additional file 5: ANOVA analysis statistics table for the PCF and
selected body sites of bacterial distribution. (XLSX 89 kb)
Additional file 6: Figure S1. PCA of pancreatic cyst fluid (PCF) and 13
body site microbiome comparisons. PCA showing the difference
between pancreatic cyst fluid and 13 different body site microbiome
selected from Human Microbiome Project database. When compared 136
bacterial genus with p < 0.01 showing high (54) and low (82) abundance
distribution between the PCF and 13 body site selected. This image
constitutes the comparison between the PCF and 13 body site
microbiomes (principal component analysis), A. PCA of antecubital fosa
and pancreatic cyst fluids microbiome, B. PCA of anterior_nares and
pancreatic cyst fluids microbiome, C. PCA of buccal_mucosa and and
pancreatic cyst fluids microbiome, D. PCA of gingiva and pancreatic cyst
fluids microbiome, E. PCA of hard_palate and pancreatic cyst fluids
microbiome, F. PCA of mid_vagina and pancreatic cyst fluids
microbiome, G. PCA of posterior_fornix and pancreatic cyst fluids
microbiome, H. PCA of palatine_tonsils and pancreatic cyst fluids
microbiome, I. PCA of retroauricular_crease and pancreatic cyst fluids
microbiome, J. PCA of stool and pancreatic cyst fluids microbiome, K.
PCA of saliva and pancreatic cyst fluids microbiome, L. PCA of
tongue_dorsum and pancreatic cyst fluids microbiome and M. PCA of
throat and pancreatic cyst fluids microbiome. Figure S2. Difference of
mean of selected high and low abundance bacterial microbiome in PCF
and 13 body sites together, respectively. Difference of mean between the
Fig. 6 Bacterial commensals of PCF and selected different body sites
comparison (HMP database) shows the difference in the distribution
uniqueness in the PCF than the body sites. One hundred thirty-six
bacterial genus of high and low abundance with P < 0.0001, and their
difference of mean is plotted with 99% confidence interval, obtained
via the Welch’s t test comparison between the groups
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bacterial genus distribution of pancreatic cyst fluid and 13 different body
site microbiome selected from Human Microbiome Project database.
When compared 17 bacterial genus (with p < 0.01) showing high
abundance in PCF and 15 bacterial genus (with p < 0.01) showing high
abundance in 13 body sites selected. (PPTX 7223 kb)
Additional file 7: Welch’s t test statistics run for the bacterial genotypes
comparison calculation of the PCF and 13 different body sites microbiota.
(XLSX 9711 kb)
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